Cargando…

Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial

OBJECTIVES: The natural history of human papillomavirus (HPV) infection has been studied extensively in young women; this study investigated HPV infection in adult women. METHODS: Data from 3817 women aged 24–45 years in a global trial of the 4-valent HPV (6/11/16/18) vaccine were used to calculate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferris, Daron G., Brown, Darron R., Giuliano, Anna R., Myers, Evan, Joura, Elmar A., Garland, Suzanne M., Kjaer, Susanne K., Perez, Gonzalo, Saah, Alfred, Luxembourg, Alain, Velicer, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453107/ https://www.ncbi.nlm.nih.gov/pubmed/32464334 http://dx.doi.org/10.1016/j.pvr.2020.100202

Ejemplares similares

Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women
por: Brown, Darron R., et al.
Publicado: (2022)

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region()
por: Castellsagué, Xavier, et al.
Publicado: (2016)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
por: Joura, Elmar A, et al.
Publicado: (2012)

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
por: Petersen, Lone K., et al.
Publicado: (2017)

Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies
por: Saah, Alfred, et al.
Publicado: (2017)

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience
por: Garland, Suzanne M., et al.
Publicado: (2016)

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
por: Castellsagué, X, et al.
Publicado: (2011)

HPV prevalence in vulvar cancer in Austria
por: Pils, Sophie, et al.
Publicado: (2017)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee
por: Taumberger, Nadja, et al.
Publicado: (2022)

International Standard Reagents for HPV Detection
por: Pagliusi, Sonia R., et al.
Publicado: (2007)

HPV screening in the urine of transpeople - A prevalence study
por: Pils, Sophie, et al.
Publicado: (2022)

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
por: Petry, Karl-Ulrich, et al.
Publicado: (2018)

What do women with gynecologic cancer know about HPV and their individual disease? A pilot study
por: Pils, Sophie, et al.
Publicado: (2014)

Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease
por: Ghelardi, Alessandro, et al.
Publicado: (2021)

IPVS statement on “Temporary HPV vaccine shortage: Implications globally to achieve equity”
por: Garland, Suzanne M., et al.
Publicado: (2020)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

HPV Clearance and the Neglected Role of Stochasticity
por: Ryser, Marc D., et al.
Publicado: (2015)

Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70
por: Chen, Zigui, et al.
Publicado: (2013)

A significant measure of HPV vaccine effectiveness in a high-risk population in Korea prior to a National Immunization Program
por: Garland, Suzanne
Publicado: (2019)

HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples
por: Cornall, Alyssa M., et al.
Publicado: (2017)

Editorial: Immunology of HPV Infection and Vaccination: Progress and Challenges
por: Licciardi, Paul V., et al.
Publicado: (2021)

Mechanistic mathematical models: An underused platform for HPV research
por: Ryser, Marc D., et al.
Publicado: (2017)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

HPV prevention and control – The way forward
por: Vorsters, Alex, et al.
Publicado: (2022)

HPV genoprevalence and HPV knowledge in young women in Mongolia, five years following a pilot 4vHPV vaccination campaign
por: Batmunkh, Tsetsegsaikhan, et al.
Publicado: (2019)

HPV DNA methylation at the early promoter and E1/E2 integrity: A comparison between HPV16, HPV18 and HPV45 in cervical cancer
por: Amaro-Filho, Sérgio Menezes, et al.
Publicado: (2018)

Attitudes toward HPV Vaccination among Women Aged 27 to 45
por: Weiss, Thomas W., et al.
Publicado: (2011)

Factors Associated With Persistence and Clearance of High-Risk Oral Human Papillomavirus (HPV) Among Participants in the HPV Infection in Men (HIM) Study
por: Bettampadi, Deepti, et al.
Publicado: (2020)

Invasive cervical cancers in the United States, Botswana and Kenya: HPV type distribution and health policy implications
por: Ermel, Aaron, et al.
Publicado: (2016)

The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models
por: Korostil, Igor A, et al.
Publicado: (2013)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix(®) or Gardasil(®) Vaccine
por: Godi, Anna, et al.
Publicado: (2015)

High coverage and adherence to dose intervals of the national school-based HPV vaccination program in Sweden during 2012–2019
por: Wang, Jiangrong, et al.
Publicado: (2023)

Decreased Ovarian Reserve Predicts Inexplicability of Recurrent Miscarriage? A Retrospective Analysis
por: Pils, Sophie, et al.
Publicado: (2016)

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
por: Olsson, Sven-Eric, et al.
Publicado: (2020)

An analysis of the knowledge of adults aged between 18 and 45 on HPV along with their attitudes and beliefs about HPV vaccine: the Cyprus case
por: Yarıcı, Filiz, et al.
Publicado: (2023)

Attitudes, Knowledge and Factors Associated with Human Papillomavirus (HPV) Vaccine Uptake in Adolescent Girls and Young Women in Victoria, Australia
por: Tung, Iris L. Y., et al.
Publicado: (2016)

European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic
por: Ciavattini, Andrea, et al.
Publicado: (2020)

Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening
por: Velentzis, Louiza S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sch067fieb5pbmgs01i909s84b